Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Production of Pharmaceuticals

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prediction of major adverse kidney events in critically ill burn patients.

Burns : journal of the International Society for Burn Injuries·2018

Same author

Undetectable haptoglobin is associated with major adverse kidney events in critically ill burn patients.

Critical care (London, England)·2017

Same author

Falsely elevated capillary glucose and ketone levels and use of skin lightening creams.

BMJ (Clinical research ed.)·2015

Same author

E. coli electroeradication on a closed loop circuit by using milli-, micro- and nanosecond pulsed electric fields: comparison between energy costs.

Bioelectrochemistry (Amsterdam, Netherlands)·2014

Same author

Optimization of protein electroextraction from microalgae by a flow process.

Bioelectrochemistry (Amsterdam, Netherlands)·2014

Same author

[Smartphone application for blood gas interpretation].

Annales de biologie clinique·2013

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Rebuilding the R&D engine in big pharma.

Jean-Pierre Garnier¹

¹GlaxoSmithKline, London. jean-pierre.garnier@gsk.com

Harvard Business Review

|June 12, 2008

Summary

Pharmaceutical companies face declining R&D productivity. GlaxoSmithKline (GSK) revitalized its research and development by empowering scientists, fostering innovation, and seeking external collaborations, leading to a significant increase in late-stage drug development.

Area of Science:

Pharmaceutical industry
Research and Development (R&D)
Drug discovery and development

Background:

The pharmaceutical sector experienced substantial financial losses between 2000 and 2008.
Factors contributing to losses include generic competition, pricing pressures, regulatory hurdles, and legal issues.
Declining R&D productivity was identified as a primary concern by industry leaders.

Purpose of the Study:

To address the issue of declining R&D productivity in the pharmaceutical industry.
To explore strategies for revitalizing the R&D engine within pharmaceutical companies.
To present GlaxoSmithKline's (GSK) approach to R&D transformation.

Main Methods:

Reorganizing R&D into focused groups led by strong leaders.

More Related Videos

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Related Experiment Videos

Last Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Encouraging internal and external scientific exploration.

Implementing process improvements and fostering a culture of innovation.

Establishing contractual relationships with academic institutions and biotech firms.

Main Results:

GSK restructured its R&D organization into 12 "centers of excellence."
The company increased its late-stage development pipeline from two to 34 products.
The strategy aimed to separate breakthrough drug discovery from best-in-class development and revised scientist incentives.

Conclusions:

Empowering scientists and fostering a culture of innovation are crucial for R&D success.
External collaborations are vital for accessing cutting-edge science.
Further efficiencies can be gained through strategies like offshoring clinical trials and targeted patient population approaches.